A topical formulation of Bosexil® shows promising results for treating psoriasis and erythematous eczema, improving scales and itch without worsening.

A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis

DPG-HERB cream is safe and effective in treating eczema, but less effective in psoriasis compared to triamcinolone acetonide cream.

Efficacy and Safety of Cream Containing Dipotassium Glycyrrhizinate, Vaccinium myrtillius, Epigallocatechin Gallatyl Glucoside, and Tamarindus indica Compared with Triamcinolone Acetonide Cream in Eczema and Psoriasis

Ixekizumab is a safe treatment for moderate-to-severe psoriasis, but patients should be aware of treatment-emergent eczematous reactions and manage them appropriately.

Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab

Dihydrochalcone derivatives from Populus balsamifera L. buds show promising antipsoriatic properties, potentially contributing to clinical improvement in psoriasis patients.

Dihydrochalcone Derivatives from Populus balsamifera L. Buds for the Treatment of Psoriasis

Topical corticosteroids are the mainstay for treating psoriasis and eczema, with coal tar as a second-choice therapy, and PUVA is frequently prescribed despite its carcinogenicity in Flanders.

Treatment policy for psoriasis and eczema: a survey among dermatologists in the Netherlands and Belgian Flanders.

Biologics for chronic plaque psoriasis can cause a switch to atopic eczema, with atopic diathesis patients more at risk.

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review

A single application of corticosteroid under a hydrocolloid dressing can effectively heal psoriasis and other dermatoses within a week, with betamethasone being the most effective treatment.

Treatment of psoriasis and other dermatoses with a single application of a corticosteroid left under a hydrocolloid occlusive dressing for one week.

IL-17 inhibitor treatment for psoriasis may cause a paradoxical shift favoring an eczematous phenotype, potentially leading to eczematous eruptions in some patients.

A Case Series of Patients With Eczematous Eruptions Following IL-17 Inhibitor Treatment for Psoriasis Vulgaris.

Secukinumab-induced eczematous eruptions can recur after switching to guselkumab for pustular psoriasis treatment, highlighting the need for careful monitoring of biologics.

Recurrence of secukinumab‐induced eczematous eruptions after guselkumab treatment for pustular psoriasis

Systemic treatments for moderate to severe plaque psoriasis show mixed results, with biologics showing the most promise for long-term control.

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Anti-TNF therapy may cause eczema as an adverse effect in 5-20% of patients with Th1-mediated inflammatory diseases, with infliximab being more strongly associated with eczema development or exacerbation.

Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review

Non-biological systemic agents, small molecules, and biologics show varying efficacy and safety in treating moderate-to-severe plaque psoriasis, with biologics showing the highest safety and effectiveness.

Biomaterial-based therapies, such as microneedles, nanoparticles, nanofibers, and hydrogels, show promise for precise and effective topical psoriasis treatment with minimal side effects and improved compliance.

Latest on biomaterial-based therapies for topical treatment of psoriasis.

Psoriasis skin has damaged barrier function, resulting in higher hydrocortisone retention, and anodal iontophoresis improves distribution into deeper layers of skin and the receptor chamber.

Topical and transdermal delivery with diseased human skin: passive and iontophoretic delivery of hydrocortisone into psoriatic and eczematous skin

Eczematized psoriasis, a common but often neglected variant of plaque psoriasis, presents with severe itching and features similar to eczema, highlighting the need for better diagnostic criteria and therapeutic options.

Eczematized psoriasis – a frequent but often neglected variant of plaque psoriasis

Paradoxical eczema can develop in patients with psoriasis receiving biologics, leading to poor disease control and treatment discontinuation.

Paradoxical eczema in patients with psoriasis receiving biologics: a case series

A new gel formulation with calcipotriol and betamethasone dipropionate is more effective, less abrasive, and more cosmetically acceptable than ointments, increasing patient choice and adherence to treatment.

What is new in topical therapy for psoriasis?

New treatments like a kinase inhibitor may offer a new approach to treating psoriasis, targeting immune cells and inflammatory pathways.

New Treatment Addressing the Pathogenesis of Psoriasis

IL-23 inhibitors are associated with a lower risk of paradoxical eczema, while increasing age and history of atopic dermatitis (HR, 1.01-1.03) increase the risk.

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.

Combining biological therapies with traditional therapies can provide complete control of psoriasis and associated comorbidities, especially in patients with comorbidities.

Latest combination therapies in psoriasis: Narrative review of the literature

What are the latest treatments for eczema and psoriasis?

These studies suggest that the latest treatments for eczema and psoriasis include topical formulations like Bosexil® and DPG-HERB cream, biologics such as ixekizumab and secukinumab, and traditional therapies like corticosteroids and coal tar, with some treatments potentially causing eczematous reactions.